Article info
Editorial
Is nucleic acid amplification point-of-care testing for chlamydia and gonorrhoea cost-effective?
- Correspondence to Dr Alec Miners, Health Services Research and Policy, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SY, UK; alec.miners{at}lshtm.ac.uk
Citation
Is nucleic acid amplification point-of-care testing for chlamydia and gonorrhoea cost-effective?
Publication history
- Accepted December 23, 2013
- First published January 15, 2014.
Online issue publication
February 12, 2014
Article Versions
- Previous version (15 January 2014).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions